Charles River experts Justin Bryans and Elizabeth Anderson join me for a spirited discussion of where we are now in oncology research. Could we ever see a world without cancer?

Manufacturing gene therapies is a hot topic in the pharma field, on both the supplier and the client ends. Joining me to discuss this issue is Charles River Associate Director of Gene Therapy, Andrew Frazer, and Purespring Therapeutics' VP of Chemistry, Manufacturing and Controls, Amanda Weiss. 

Dr. Lauren Black and Dr. Monkol Lek are both committed to the research and advancement of rare disease treatments. But when you are trying to treat just one patient, what can you learn that could help many more? We discuss the importance of n-of-1 studies, not just for that one patient and their families, but for anyone who might someday need a rare cure.

Through his own first-hand experience, Charles River Senior Director of Global Talent Acquisition Michael Hakeem knows the importance of diversity in hiring. He joins us this Pride Month to talk about his experiences and his insight into a thoughtful approach to recruiting for a company as large as Charles River.

Jesse McCool from Wheeler Bio and Ian Wyllie from Charles River's RightSource℠ program join me to discuss the manufacturing of biologics from both ends: getting from development to first in human, and quality control. 

Mycologist Ziva Abraham discusses fungal detection and identification in cleanrooms, and whether the TV show The Last of Us portrays a realistic fungal zombie apocalypse.

This month I am joined by Romaine Wright, Program Manager for Learning and Development for Charles River, to discuss allyship in the workplace. How can we use whatever privileges we have to help our colleagues and build a more diverse workforce?

This month I am joined by Dr. Elise Lewis, principal director of toxicology for Charles River's Horsham, Pennsylvania site. As a woman of color in the scientific field, she is passionate about mentoring the scientists of tomorrow. 

She can also be seen in this interview with Fox 29 Philadelphia: https://www.fox29.com/video/902459

In vivo models have been the drug safety standard for as long as there have been drug safety standards. With mounting data proving the worth of in vitro models, could there be a future where we will not need in vivo? I am joined by Anjli Venkateswaran, Director of Strategic Partnerships for Charles River, to discuss this trending topic.

This year Charles River celebrated its 75th anniversary. To help me reminisce about how far the company and science in general have come in that time, I invited Chief Commercial Officer Bill Barbo to chat. He started at Charles River in 1982 as a scientist, and has seen the company grow and change along with advances in science.